Marjo Kuortti

University of Tampere, Tammerfors, Province of Western Finland, Finland

Are you Marjo Kuortti?

Claim your profile

Publications (4)58.22 Total impact

  • Marjo Kuortti · Pirjo Lindfors ·
    [Show abstract] [Hide abstract]
    ABSTRACT: This study introduces Finnish girls’ views on and explanations for the factors contributing to their decisions concerning their first sexual intercourse. The data consists of personal interviews with girls aged 16–19, and stories produced through process drama. The analysis was conducted by narrative methods. Two model story categories of the first sexual intercourse stories were constructed: the close relationship and the casual relationship. The close relationship category consists of elements of two sub-stories: the conventional and the planned love story. The casual relationship category consists of elements of the tragic love, the teenage party and the experience-seeking sub-stories. Being prepared for sex was a shared plot element in all of the first intercourse stories. In the close relationship category the other major explanatory factors were mutual love and a steady relationship. In the casual relationship category the explanatory factors were girl’s affection for the partner without a relationship or getting experience, respectively. The girls’ agency in the use of contraception and the intercourse itself differed between the sub-stories. Girls regarded intercourse as an important step towards their womanhood. Those who work with teenagers should be aware of these stories in order to reinforce those stories where teenagers are active agents.
    Sexuality & Culture 09/2014; 18(3). DOI:10.1007/s12119-013-9206-1
  • Source
    Marjo Kuortti · Elise Kosunen ·
    [Show abstract] [Hide abstract]
    ABSTRACT: To investigate associations between sexual behaviour and risk-taking health behaviour among adolescent females in our changing sexual culture. A questionnaire study. Girls who had had multiple sexual partners (at least five in their lifetime or four during the last six months) were compared with those with fewer partners. Logistic regression was applied. The Adolescent Clinic, a primary healthcare unit in the city of Tampere, Finland. A sample of 247 female clients aged 15-18 years who had experienced sexual intercourse. Contraceptive practices, substance use, and sexual attitudes. Girls with multiple sexual partners (n = 69) and the reference group (n = 178) did not differ from each other significantly by age, age at menarche, or educational status. In univariate analysis, age at sexual debut, contraceptive practices, and various substance uses were strongly associated with having multiple sexual partners. Ever-use of emergency contraception was marginally associated, while ever-use of conventional hormonal contraception or condoms was not. In multivariate analysis, low age at sexual debut (OR 8.75 for age 11-13), omitting contraception at the most recent intercourse (OR 3.48), ever-use of withdrawal as a contraceptive method (OR 2.34), and repeated use of drugs (OR 4.10) were associated with having multiple sexual partners. Different types of risk-taking behaviour are still interlinked. In discussions with adolescents showing one type of risk behaviour health service providers should make an effort to identify other modes of risk-taking.
    Scandinavian journal of primary health care 02/2009; 27(1):47-52. DOI:10.1080/02813430802691933 · 1.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate a quadrivalent vaccine against HPV types 6, 11, 16, and 18 (HPV-6/11/16/18) for the prevention of high-grade cervical lesions associated with HPV-16 and HPV-18. METHODS: In this randomized, double-blind trial, we assigned 12,167 women between the ages of 15 and 26 years to receive three doses of either HPV-6/11/16/18 vaccine or placebo, administered at day 1, month 2, and month 6. The primary analysis was performed for a per-protocol susceptible population that included 5305 women in the vaccine group and 5260 in the placebo group who had no virologic evidence of infection with HPV-16 or HPV-18 through 1 month after the third dose (month 7). The primary composite end point was cervical intraepithelial neoplasia grade 2 or 3, adenocarcinoma in situ, or cervical cancer related to HPV-16 or HPV-18. RESULTS: Subjects were followed for an average of 3 years after receiving the first dose of vaccine or placebo. Vaccine efficacy for the prevention of the primary composite end point was 98% (95.89% confidence interval [CI], 86 to 100) in the per-protocol susceptible population and 44% (95% CI, 26 to 58) in an intention-to-treat population of all women who had undergone randomization (those with or without previous infection). The estimated vaccine efficacy against all high-grade cervical lesions, regardless of causal HPV type, in this intention-to-treat population was 17% (95% CI, 1 to 31). CONCLUSIONS: In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV-16 or HPV-18 than did those in the placebo group.
    New England Journal of Medicine 05/2007; 356(19):1915-1927. DOI:10.1056/NEJMoa061741 · 55.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We evaluated a study setting for assessment of the long-term vaccine efficacy (VE) of human papillomavirus (HPV) virus-like-particle (VLP) vaccine against cervical carcinoma. A total of 22,412 16- to 17-year old adolescent women from seven cities in Finland were invited by letter to participate in a phase III study of a quadrivalent HPV (types 6, 11, 16, 18) VLP vaccine, between September 2002 and March 2003. A total of 30,947 18-year old women were invited to participate as unvaccinated controls. These women were asked about their willingness to participate in an HPV vaccination trial and to fill a health questionnaire. These three population-based cohorts of adolescent women, including women vaccinated with HPV vaccine or placebo vaccine and unvaccinated control women, are systematically followed over time. The study cohort database will be linked with the Finnish Cancer Registry using cervical carcinoma in situ (CIS) and invasive cervical carcinoma (ICC) as endpoints. Assuming that the cumulative incidence of CIS and ICC over 15 years is 0.45%, and that there is no loss to follow-up, and power of 80%, the determination of 70% total VE will require 3357 HPV vaccine recipients, 3357 placebo vaccine recipients, and 6714 unvaccinated controls. At the baseline, 2632 (12%) of the invited adolescents volunteered to the phase III vaccination trial, and 6790 (22%) responded to the questionnaire study. During a recruitment period of 10 months, 874 HPV vaccine recipients, 875 placebo recipients and 1919 unvaccinated controls were enrolled. Population-based enrollment of large cohorts of vaccinated and unvaccinated adolescents for passive registry-based follow-up with cervical carcinoma as the end-point is feasible and currently going on in Finland.
    International Journal of STD & AIDS 05/2006; 17(4):237-46. DOI:10.1258/095646206776253453 · 1.05 Impact Factor